Sanj Patel, CEO, stated that "ARCALYST revenue continues to grow, driven by the expanding adoption of IL-1 alpha and beta inhibition across the recurrent pericarditis population." He highlighted a 65% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results